Ocera Therapeutics, Inc. (OCRX) Sees Large Decline in Short Interest
Ocera Therapeutics, Inc. (NASDAQ:OCRX) was the target of a large decrease in short interest during the month of October. As of October 13th, there was short interest totalling 410,544 shares, a decrease of 43.7% from the September 29th total of 728,662 shares. Based on an average daily volume of 400,728 shares, the short-interest ratio is currently 1.0 days. Currently, 1.9% of the company’s shares are short sold.
An institutional investor recently raised its position in Ocera Therapeutics stock. Virtu KCG Holdings LLC increased its holdings in Ocera Therapeutics, Inc. (NASDAQ:OCRX) by 194.6% in the second quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The firm owned 213,531 shares of the biopharmaceutical company’s stock after purchasing an additional 141,040 shares during the period. Virtu KCG Holdings LLC owned 0.81% of Ocera Therapeutics worth $248,000 as of its most recent SEC filing. Institutional investors and hedge funds own 20.25% of the company’s stock.
Ocera Therapeutics (NASDAQ OCRX) opened at 1.03 on Friday. The stock has a 50 day moving average price of $1.07 and a 200 day moving average price of $1.11. The firm’s market cap is $27.31 million. Ocera Therapeutics has a 52 week low of $0.52 and a 52 week high of $2.95.
Ocera Therapeutics (NASDAQ:OCRX) last announced its quarterly earnings data on Thursday, August 3rd. The biopharmaceutical company reported ($0.23) EPS for the quarter, beating the Zacks’ consensus estimate of ($0.24) by $0.01. Equities research analysts expect that Ocera Therapeutics will post ($1.20) EPS for the current year.
Separately, Zacks Investment Research raised Ocera Therapeutics from a “sell” rating to a “hold” rating in a research note on Wednesday, August 2nd. Three investment analysts have rated the stock with a hold rating and two have given a buy rating to the company’s stock. The company currently has a consensus rating of “Hold” and a consensus price target of $2.25.
Ocera Therapeutics Company Profile
Ocera Therapeutics, Inc is a clinical-stage biopharmaceutical company. The Company is focused on acute and chronic orphan liver diseases. The Company is focused on the development and commercialization of its clinical candidate, OCR-002, for the treatment of hepatic encephalopathy (HE). OCR-002 is a molecule, ornithine phenylacetate, which functions as an ammonia scavenger.
Receive News & Ratings for Ocera Therapeutics Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Ocera Therapeutics Inc. and related companies with MarketBeat.com's FREE daily email newsletter.